Lipidomic changes in persister cancer cells drive enhanced ferroptosis sensitivity.

ABSTRACT:

Aims

Unique in the broader category of drug-resistant cells, persister cancer cells (PSs) acquire their tolerance to compounds through reversible, chromatin-mediated changes, allowing them to 'persist' in the face of cancer therapeutic agents. PSs are implicated in minimal residual disease from which cancer relapse occurs, and given their established sensitivity to ferroptosis, PSs present a critical point through which identification and targeting of drug-resistant cancers may be possible. Ferroptosis sensitivity in drug-resistant cancers may be caused by the attainment of the persister state, or it may merely be correlative with this state and due instead to extended inhibition of oncogenic signaling or the induction of chemotherapy stress. Nonetheless, ferroptosis sensitivity ha

SUBMITTER: Reznik E 

PROVIDER: S-EPMC12739762 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature